Рациональный отбор контрольной группы для рандомизированных исследований при диссеминированном почечно-клеточном раке

1. Atzpodien J., Kirchner H., Illiger H.J., Metzner B., Ukena D., Schott H., Funke P.J., Gramatzki M., Jurgenson S., Wandert T., Patzelt T., Reitz M.: IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. // Br. J. Cancer. — 2001;85:1130—1136.

2. Flanigan R., Salmon S., Blumenstein B., Bearman I.S., Roy V., MacGrath P., Caton J., Munshi N., Crawford E.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. // New Engl. J. Med. — 2001;345: 1655—1659.

3. Fossa S., Droz J.P., Pavone-Macaluso M., Debruyne F., Vermeylen K., Sylvester R. and members of the EORTC-GU group: Vinblastine in Metastatic Renal Cell Carcinoma: EORTC Phase III Trial 30882. // Eur. J. Cancer. — 1992;28a: 878—880.

4. Fossa S., Martinelli G., Otto U., Schneider G., Wander H., Oberling F., Bauer H., Achtnicht U., Holdener E: Recombinant interferon alfa-2( with or without vinblastine in metastatic renal cell carcinoma: Results of a European multicenter phase III study. // An. Oncol. — 1992;3: 301—305.

5. Jones M., Selby P., Frances C.: The impact of Interleukine-2 on survival in renal cancer: a multivariate analysis. // Canc. Bioth. — 1993; 8: 275—282.

6. Medical Research Council Renal Cancer Collaborators. Interferon-(and survival in metastatic renal carcinoma: early results of a randomised controlled trial. // The Lancet. — 1999;353:14—17.

7. Mickisch G., Carballido J., Hellsten S., Schulze H., Mensink H.: Guidelines on Renal CellCancer. // Eur. Urol.- 2001;140: 252—255.

8. Mickisch G., Garin A., Van Poppel H., De Prijck L., Sylvester R.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial. // The Lancet. — 2001;358: 966—970.

9. Motzer R., Bacik J., Murphy B., Russo P., Mazumdar M.: Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. // J. Clin. Oncol. — 2002;20:289—296.

10. Motzer R., Mazumdar M., Bacik J., Russo P., Berg W., Metz E.: Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma. // J. Clin. Oncol. — 2000;18: 1928—1935.

11. Motzer R., Murphy B., Bacik J., Schwartz L., Nanus D., Mariani T., Loehrer P., Wilding G., Fairclough D., Cella D., Mazumdar M.: Phase III Trial of Interferon Alfa-2( With of Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma. // J. Clin. Oncol. — 2000; 18: 2972—2980.

12. Negrier S., Caty A., Lesimple T., Douillard J., Escudier B., Rossi J.: Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without Fluorouracil.// J. Clin. Oncol. — 2000;18: 4009—4015.

13. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., Ravoud A., Mercatello A., Peny J., Mousseau M., Philip T., Tursz T.: Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2(, or Both in Metastatic Renal-Cell Carcinoma. // New Engl. J. Med. — 2000;338:1272—1278.

14. Palmer P.A., Vinke J., Philip T., Evers P.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. // Ann. Oncol. — 1992;3: 475—480.

15. Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., Juusela H., Rintala E., Hietanen P., Kellokumpu-Lehtinen P.L.: Prospective Randomized Trial of Interferon Alfa-(2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Carcinoma. // J. Clin. Oncol. — 1999;17: 2859—2870.